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therapy, prior authorization, not in formulary) between January 1, 2005 to December
31, 2006 but who subsequently ﬁ lled an SGA or conventional antipsychotic within six 
months of the rejected claim, formed the case group (n  328). Newly initiated anti-
psychotic users who were in health plans with an open formulary and thus did not 
experience rejection of an SGA claim formed the control group (n  1097). All patients
were followed up for 13 months. Cox regression models were used to estimate the 
effect of having rejected claims on all-cause discontinuation of the index drug, deﬁ ned
as discontinuation, add-on or switch. The model controlled for age, sex, co-morbidities, 
geographic locations, index drug, prescription and co-payment. RESULTS: Reasons
for rejected claims were distributed as follows: 1) drug not on formulary (72.9%); 2)
required prior authorization (19.5%); and 3) required step therapy (7.6%). Median 
time to discontinuation was 120 days for the case group and 127 days for the control 
group. The adjusted hazard for discontinuation of the index drug (HR  1.29, 95% 
CI: 1.08–1.53) was signiﬁ cantly higher for patients with rejected initial SGA claims
compared to controls. Co-payments ranging from $20 to $39 were associated with
lower discontinuation compared with copayment ranging from $0 to $4 (HR  0.75, 
95% CI: 0.60–0.93). CONCLUSIONS: New antipsychotic users with rejected initial 
SGA claims due to formulary restrictions were more likely to discontinue their anti-
psychotic drugs compared to users who did not face such restrictions.
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OBJECTIVES: To assess the association between self-perceived copay burden and
medication adherence among patients with schizophrenia. METHODS: Data were 
collected from December 2007 to February 2008 from a web-based consumer panel. 
Adults (age 18) self-reporting a diagnosis of schizophrenia were invited to participate
in the study through self-reported questionnaires on both the internet and through 43 
interview facilities across the US. Inclusion criteria for analysis were: current use of 
an SGA, and no exposure to clozapine or a depot formulation antipsychotic. Adher-
ence was assessed using the MMAS, with general adherence deﬁ ned as MMAS  2, 
and complete adherence deﬁ ned as MMAS  1. Logistic regression models were
developed to assess the effects of self-perceived copay burden on adherence while
adjusting for demographics, substance use, concomitant psychotropic medications,
comorbidities, and health insurance. RESULTS: Of the 351 study respondents who 
met the criteria for analysis, 39% (n  137) perceived experiencing burden from their 
medication copays. Adjusting for covariates, the effects of copay burden on general
adherence approached but did not reach signiﬁ cance (p  0.060). However, patients
who experienced a copay burden were less than half as likely to have complete adher-
ence [OR  0.427; 95% CI: (0.257, 0.711); p  0.001]. Effects of copay burden on 
the individual components of the MMAS varied. Patients with copay burden were 
more likely to forget to take medication [OR  2.058; 95% CI: (1.270, 3.335); p 
0.003] and to discontinue medication when feeling worse [OR  2.000; 95% CI: 
(1.140, 3.507); p  0.016]. Being careless about taking medication and discontinuing
medication when feeling better were not signiﬁ cantly affected by copay burden. 
CONCLUSIONS: Among patients with schizophrenia using SGAs, copay burden is
associated with forgetting to take medication, discontinuing medication when feeling
worse, and lesser likelihood of complete adherence. Less restrictive formularies that
reduce copay burden for SGAs may have a positive effect on medication adherence 
among patients with schizophrenia.
PMH46
PREDICTORS OF DULOXETINE TREATMENT PERSISTENCE FOR
PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Gelwicks SC1, Faries DE1, Ye W1, Liu X2
1Lilly USA, LLC, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Treatment of depression is often accompanied by discontinuation and
switching of antidepressant medications. Information on factors predicting persistence
(and avoidance of switching) would thus be of value to medical decision makers. We
assess the impact of demographics, initial dose, prior medications, and comorbidities
on duloxetine treatment persistence for patients with major depressive disorder
(MDD) using retrospective claims data. METHODS: Using the PharMetrics Database,
we studied individuals aged 18–64 who initiated duloxetine treatment between April 
2005 and March 2006, had q1 prior MDD diagnosis, and had continuous insurance
coverage 6 months before and 12 months after initiation. Persistence was deﬁ ned as
q3 months’ continuous duloxetine treatment. Stepwise logistic regression and tree
analyses of demographics, initial dose, prior medications, and comorbidities assessed
predictors of persistence. Sensitivity analysis was done by analyzing factors associated 
with switching to venlafaxine XR or a selective serotonin reuptake inhibitor (SSRI)
within a year of initiating duloxetine. RESULTS: Among 9,148 patients (74.1%
female; mean age  45.6, SD  11.1) who initiated duloxetine treatment, 63.5% had
persistence of duloxetine treatment for q3 months. Regression results showed the most 
signiﬁ cant factors for persistence to be initial dose of q60 mg QD (OR  1.38), age
group of 46–64 yrs (OR vs. age 18–25 yrs  1.63), and venlafaxine XR/SSRI use in 
the prior 3 months (OR  1.64) (all p-values  .001). Sensitivity analysis showed initial 
dose of 60 mg QD was associated with switching from duloxetine (OR  1.22), 
although other factors showed differences from the persistence analysis. CONCLU-
SIONS: The results suggest that for MDD patients, initial dose, age group, and recent 
venlafaxine XR/SSRI use predict persistence on duloxetine treatment. Sensitivity 
analysis on switching showed a consistent effect of initial dose.
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OBJECTIVES: To assess the reasons for discontinuation and for continuation of 
antipsychotic medication in the treatment of schizophrenia from patient and clinician 
perspectives. METHODS: Two measures were developed to assess the Reasons for
Antipsychotic Discontinuation/Continuation (RAD), one from patient’s perspective 
(RAD-I), and the other from clinician’s perspective (RAD-Q). These measures were
administered to patients enrolled in a 12-week study of antipsychotic medication in 
the treatment of schizophrenia (N  630). Reasons for discontinuation and reasons 
for continuation with the assigned antipsychotic during the study were assessed. 
Reported reasons were rated as being a primary reason, very important, somewhat 
important, or of minor importance. The top primary reasons for medication discon-
tinuation and continuation were identiﬁ ed from patient and clinician perspectives, and 
level of concordance between patients’ and clinicians’ reasons was assessed. RESULTS:
The top primary reasons for medication discontinuation differed from the top primary 
reasons for continuation on the medication, with a high level of concordance between 
patients’ and clinicians’ perspectives. The top three primary reasons for medication
discontinuation were insufﬁ cient improvement or worsening of positive symptoms, 
medication-related adverse events, and insufﬁ cient improvement or worsening of 
mood symptoms. The top three primary reasons for medication continuation were
improvement in positive symptoms, subjective perception of improvement, and 
improvement in level of functioning. CONCLUSIONS: Medication efﬁ cacy appears 
to be the core driver of medication continuation and discontinuation, especially with
regard to positive symptoms. Reasons for medication discontinuation differ somewhat 
from reasons for continuation, with a high level of concordance between patients’ and 
clinicians’ perspectives.
PMH48
BURDEN OF ILLNESS OF DEPRESSION SYMPTOMS AMONG PATIENTS 
WITH TYPE 2 DIABETES MELLITUS
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OBJECTIVES: The purpose of this analysis is to quantify the additive burden associ-
ated with experiencing depression symptoms in patients with type-2 diabetes mellitus 
(T2DM). METHODS: Data were from the 2008 US National Health and Wellness 
Survey (NHWS), an annual cross-sectional survey of self-reported health care atti-
tudes, behaviors, disease states, and outcomes of adults aged 18. Analyses were 
limited to respondents self-reporting a diagnosis of T2DM. Depression symptoms were
deﬁ ned as an afﬁ rmative response in the past month to: bothered by feeling down, 
depressed or hopeless; or bothered by having little interest or pleasure in doing things.
Outcomes included health care utilization in the past six months, work productivity 
as measured by the Work Productivity and Activity Impairment (WPAI) questionnaire, 
and SF-12v2 summary scores. Logistic and linear regression models were developed
to assess independent effects of depression on outcomes, while adjusting for demo-
graphics and co-morbidity. RESULTS: Among patients with T2DM, 38% self-reported 
depression symptoms. Adjusting for demographics and co-morbidity, patients with
depression symptoms were 1.7 (p  0.001) times as likely to visit the emergency room, 
1.6 (p  0.001) times as likely to be hospitalized, and had 2.2 (p  0.001) additional 
provider visits compared to T2DM patients without depression symptoms. Depression
symptoms were also associated with 21.4% (p  0.001) greater impairment in daily
activities and a decrease in SF-12v2 physical and mental summary scores of 4.0 (p 
0.001) and 12.7 (p  0.001) points, respectively. Among patients who were employed
full-time, depression symptoms were associated with 4.3% (p  0.001) greater missed 
work time, 15.2% (p  0.001) greater lost productivity while working, and 13.4% (p
 0.001) greater overall work impairment. CONCLUSIONS: In patients with T2DM, 
depression symptoms were associated with signiﬁ cant burden on health care utiliza-
tion, work productivity, and health-related quality of life. Proper treatment of both
T2DM and co-morbid depression in this population may reduce humanistic and eco-
nomic burden of disease.
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OBJECTIVES: Type 2 Diabetes Mellitus (T2DM) is an adult-onset, chronic, metabolic 
disorder that affects approximately 23.5 million adults in the United States and 
requires management with daily medications, blood glucose monitoring, regular 
HbA1c assessments, diet, and exercise. If T2DM patients also have difﬁ culties
with planning, working memory, and organization, their health problems may 
be compounded due to inappropriate management of their chronic health condition. 
The current study sought to estimate the prevalence of T2DM patients with the 
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co-occurrence of symptoms of Attention Deﬁ cit Hyperactivity Disorder (ADHD), a
neurobehavioral condition that impairs organization and executive planning that
affects between 1–6% of adults in the United States. METHODS: The study design 
utilized an internet-based panel of 567 T2DM cases that consented to participate in 
a survey. In addition to de-identiﬁ ed demographic data, respondents were asked to
provide information on diabetes self-care, HbA1c values, ADHD symptoms, and 
health care resource utilization. RESULTS: The results indicated that those respon-
dents who had symptoms of ADHD had more ofﬁ ce visits for diabetes-related issues 
(p  .0002), more ofﬁ ce visits for illness or injury (p  .0007), and more hospitaliza-
tions for illness or injury (p  .0493) compared with T2DM respondents without
symptoms of ADHD. For those who reported HbA1c values, regression tree analyses
suggested low diabetes self-care scores and high ADHD symptom scores were associ-
ated with worse HbA1c values. CONCLUSIONS: These ﬁ ndings suggest that the co-
occurrence of T2DM and ADHD symptoms could result in poor HbA1c management
and may lead to increased resource utilization.
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OBJECTIVES: Functioning in severe mental disorders is very important and brief 
rating instruments are needed. Personal and Social Performance Scale (PSP) is one of 
the instruments which can be used in severe mental disorders in a short time.
METHODS: The study was performed in the psychiatry departments of two university 
hospitals. In- or outpatients diagnosed as schizophrenia or bipolar disorder were
included in the study. Exclusion criteria were comorbidity of other psychiatric disorders
(including substance use disorders) and physical diseases. For concurrent validity,
besides PSP, Clinical Global Impression (CGI), Global Assessment of Functioning
(GAF) of DSM-IV, Quality of Life and Satisfaction Questionnaire (QLS-Q), and Posi-
tive and Negative Schizophrenia Scale (PANSS) were used. For discriminant validity,
the mean scores of PSP of patients with and without symptomatic remission were
compared. RESULTS: The study was carried out with a total of 135 patients, 105
(77.8%) diagnosed as schizophrenia and 30 (22.2%) diagnosed as bipolar disorder. 
The mean age of the patients was 34.1 o 10.7 and 75 (55.6%) of them were male. The
duration of illness was 10.4 o 7.5 years. The mean score of PSP was 60.0 o 17.1. In
the reliability analysis, the Cronbach alpha coefﬁ cient was 0.8327, and item-total score
correlations were between 0.4920–0.7462. In the validity analyses, the total score of 
PSP was signiﬁ cantly correlated with the total score of CGI (r  0.854, p  0.0001), 
GAF (r  0.748, p  0.0001), QLS-Q (r  0.734, p  0.0001), and PANSS (r  0.664, 
p  0.0001). The difference between the patients with and without symptomatic remis-
sion was signiﬁ cant (54.8 o 14.8 vs. 72.6 o 9.8, t  7.434, p  0.0001). CONCLU-
SIONS: The Turkish version of PSP was found to be reliable and valid in severe mental
disorders. It can be used both in clinical trials and routine follow-up.
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OBJECTIVES: The Life Participation Scale for Children was designed to measure
treatment-related improvements in adaptive functioning in children with ADHD. To
measure these attributes in adult subjects, we developed a Life Participation Scale for 
Adults (LPS-A). METHODS: LPS-A items were selected by convening focus groups, 
interviewing experts, and performing structured cognitive interviews to improve item
wording. These were administered in a 2-week study of treated (N  10) and untreated 
(N  10) participants with ADHD and normal controls (N  11). Cronbach’s alpha,
Lin’s concordance correlation, and Pearson’s correlations were used to assess internal
consistency, test-retest reliability, and convergent/divergent validity. LPS-A scores were
compared for ADHD/control, treated/untreated, and less/more severe participants to 
measure discriminant validity. RESULTS: The LPS-A demonstrated internal consis-
tency (Cronbach’s alpha  0.92–0.96). Concordance correlations indicated test-retest 
reliability (r  0.79 to 0.86). Convergent, divergent, and discriminant validity were 
demonstrated. CONCLUSIONS: The initial examination of the LPS-A suggests accept-
able levels of validity and reliability. Larger studies will provide further information 
about the psychometric properties of the LPS-A. The LPS-A appears to be a promising 
new instrument for measuring adaptive function in adults with ADHD.
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EVALUATING CENTRAL NERVOUS SYSTEM DRUG LABELS FOR
PATIENT-REPORTED OUTCOMES CLAIMS
Viswanathan S, Gemmen EK, Bharmal M
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OBJECTIVES: Previous studies (prior to 2003) have suggested that central nervous 
system (CNS) drugs have had the highest number of patient-reported outcomes (PRO)
claims used in product approvals. This study examined the use of PRO as efﬁ cacy 
endpoints in label claims of recent FDA-approved CNS drugs between 2003 and 2008. 
METHODS: Product labels of FDA-approved prescription-only New Molecular Enti-
ties (NMEs) from the CNS drug category between January 2003 and October 2008 
were reviewed. The most recent product label, obtained either from the FDA’s Center
for Drug Evaluation and Research (CDER) or directly from the company website, was 
used for all the drugs, including the drugs withdrawn from the market. Efﬁ cacy end-
point data was obtained from the Clinical Studies section of the approved product 
label. Efﬁ cacy measures were categorized into PRO, clinician-reported outcomes
(CRO) and laboratory devices. RESULTS: During the ﬁ ve year period, 14 of the 153
FDA-approved NMEs were CNS agents. The CNS agents included four drugs for 
neuromuscular disorders, two antipsychotics, two antidepressants, two sedatives, one
smoking cessation drug, one analgesic, one CNS stimulant, and one drug treating 
alcoholism. Of the 28 efﬁ cacy measures used in the CNS product labels, seven (25%) 
were PRO. The four drugs using PRO endpoints included one antidepressant, one
analgesic, one CNS stimulant and one smoking cessation drug. Of the seven PRO 
used, three were symptom scales, two were global impression scales, one scale mea-
sured condition-speciﬁ c health-related quality-of-life, and one scale measured func-
tional impairment. The percentage of approved CNS drugs using PRO as efﬁ cacy
endpoints in label claims declined since 2002 (2003–08: 28.5%; 1997–2002: 75%). 
CONCLUSIONS: The latter half of the past decade has seen a considerable decrease 
in the number of CNS drugs that have had PRO-based label claims. Symptoms scales 
are the prominent type of PRO used in CNS drug label claims.
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OBJECTIVES: To identify the clinical outcomes associated with self-perceived copay 
burden among patients with schizophrenia. METHODS: Data were taken from a 
nationwide survey of adults (age 18) with a self-reported diagnosis of schizophrenia.
The survey was ﬁ elded from December 2007 to February 2008. Data were collected 
through both self-reported questionnaires administered on-site, and via the Internet.
Inclusion criteria for analysis were no exposure to clozapine, no use of a depot injec-
tion of an antipsychotic, and currently using a second generation antipsychotic (SGA). 
Outcomes included emergency room (ER) visits, hospitalization, suicide attempt, 
missed work (among employed patients), as well as experiencing severe distress deﬁ ned 
as a score of 0–60 on the Psychological General Well Being (PGWB) scale. Assessment
of the effects of self-perceived copay burden on outcomes was calculated using logistic
regression models. Demographics, substance use, concomitant psychotropic medica-
tions, comorbidity, and health insurance were controlled for in the models. RESULTS:
Of the patients who met the inclusion criteria (n  351), 39% (n  137) self-reported 
experiencing copay burden. Adjusting for covariates, patients who experienced copay
burden were more likely to use the ER [OR  2.157; 95% CI:(1.322, 3.520); p 
0.002], have a hospitalization [OR  2.512; 95% CI: (1.475, 4.277); p  0.001], have 
a suicide attempt [OR  2.385; 95% CI: (1.156, 4.920); p  0.019], and experience
severe psychological distress [OR  1.833; 95% CI: (1.092, 3.075); p  0.022]. Among 
the 110 patients who were employed, those who experienced copay burden were more 
likely to have missed work in the past month [OR  7.193; 95% CI: (2.554, 20.256);
p  0.001]. CONCLUSIONS: Among patients with schizophrenia using SGAs, greater 
copay burden was associated with increased ER visits, hospitalization, suicide 
attempts, missed work, and psychological distress. Patient’s health care use and psy-
chological well being are likely to beneﬁ t from less restrictive formularies that reduce 
copay burden for antipsychotic medication.
PMH54
PATIENT-REPORTED HEALTH STATUS IN CHRONIC MEDICAL DISORDER
PATIENTS WITH AND WITHOUT DEPRESSION IN THE UNITED STATES, 
2004–2005
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
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OBJECTIVES: Our objective was to examine the association of health status measures
with depression diagnosis in chronic medical disorder (CMD) patients. METHODS:
For the retrospective analysis, we extracted data on / 18 year-old employed adults 
from the pooled 2004–5 Medical Expenditure Panel Survey. Data included ICD-9-
CM-coded CMD (hyperlipidemia, heart-disease, arthritis/other joint-disorders, 
chronic obstructive pulmonary disease, hypertension, or diabetes), depression, age,
gender, race, poverty-level, health-insurance, urban-residence, and any depression 
treatment (psychotherapy or antidepressant) and patient-reported health-status mea-
sures (physical component summary, PCS, and mental component summary, MCS 
scores from the Short-Form 12 (SF-12); patient health questionnaire, PHQ-2; and 
Kessler Index, K6) on a continuous scale. We compared mean and standard deviation 
of health status measures in CMD patients with and without depression using t-tests. 
We weighted sample estimates and calculated 95 percent conﬁ dence limits (CL) using 
the Taylor expansion method. In multivariate logistic regression analyses, after con-
trolling for other characteristics, we examined the association of health status mea-
sures with depression diagnosis. RESULTS: Health status signiﬁ cantly differed in
CMD patients with and without depression (n  9,738, Means; SF-12 PCS 48.25 vs.
50, SF-12 MCS 43.76 vs. 52.03, PHQ-2 1.59 vs. 0.53, and K6 6.3 vs. 2.9, all 
p  0.001). Increasing scores on the SF-12 PCS and SF-12 MCS decreased the odds 
of depression while increasing scores on the PHQ-2 and K6 increased the odds of 
depression. In a multivariate model, after adjusting for covariates, the SF-12 MCS (a 
one-unit increase resulted in 0.97 times the risk for depression, 95%CL: 0.95–0.99, 
p  0.0009) and the PHQ-2 (a one-unit increase results in 1.2 times the risk for 
depression, 95%CL: 1.07–1.35, p  0.0022) were signiﬁ cantly associated with depres-
